Investigating shared mechanisms of tau toxicity in neurodegenerative diseases
Shared Mechanisms of Tau Toxicity Among Neurodegenerative Diseases
This study is looking at how problems with a protein called tau might be linked to diseases like Alzheimer's and Frontotemporal Dementia, with the hope of finding new ways to treat these conditions that could help patients in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11130576 on NIH RePORTER |
What this research studies
This research explores the common pathological features of neurodegenerative diseases, particularly focusing on the role of tau protein abnormalities. By examining how tau hyperphosphorylation and aggregation contribute to conditions like Alzheimer's disease and Frontotemporal Dementia, the study aims to identify shared mechanisms that could be targeted therapeutically. The research utilizes advanced techniques, including CRISPR technology, to manipulate tau levels and assess their impact on mitochondrial function and disease progression. Patients may benefit from insights that could lead to new treatment strategies for a range of neurodegenerative disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, Frontotemporal Dementia, or other tau-related neurodegenerative disorders.
Not a fit: Patients with neurodegenerative diseases not associated with tau pathology, such as certain forms of motor neuron disease, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that alleviate symptoms or slow the progression of multiple neurodegenerative diseases.
How similar studies have performed: Previous research has shown promising results in targeting tau abnormalities in animal models, suggesting potential for success in human applications.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Lu, Bingwei — Stanford University
- Study coordinator: Lu, Bingwei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.